ArticlePharmacoEconomics - open2026
The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland.
Article in PharmacoEconomics - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur study examines the consistency and transferability of cost-effectiveness values, specifically the incremental cost-effectiveness ratio (ICER), focusing on several disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) approved by four of the most established Health Technology Assessment (HTA) bodies.
methodsData of economic evaluation results for DMTs were extracted from the HTA reports published by four agencies. Descriptive statistics were employed to identify correlations between the accepted ICERs within and across agencies. Two different currency conversion approaches were employed to investigate the feasibility and efficiency for transferring accepted ICERs across jurisdictions.
resultsThe study analysed ten DMTs that received positive recommendations from four agencies: the National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC), Pharmaceutical Benefits Advisory Committee (PBAC) and Canada's Drug Agency (CDA). The consistency of accepted ICER values for the class of DMTs was observed within the four agencies; however, the commonality of accepted ICER values was only observed between some agencies, such as the CDA and NICE, as well as the PBAC and SMC. Purchasing power parity-adjusted ICER values were found to provide better transference of ICER outcomes as compared to the exchange-rate method.
conclusionThis study highlighted the consistency of the economic evaluation for DMTs within the four agencies. We also identified a particularly strong alignment between NICE and the CDA, as well as the PBAC and SMC. Additionally, the examination of two ICER value conversion methods pinpointed key factors that could impact the transference of ICER values.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.